ABCG2 and non-small cell lung carcinoma: In summary, this pharmacogenetic study demonstrates that platinum efflux transporter gene ABCG2 polymorphism was divergently associated with objective response and overall survival of NSCLC patients receiving platinum-based chemotherapy, and its interaction with the platinum import transporter gene SLC31A1 polymorphism was also associated with clinical outcomes.